Amphastar Pharmaceuticals AMPH EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Amphastar Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's EBITDA margin?
- Amphastar Pharmaceuticals (AMPH) reported EBITDA margin of 24.2% in Q1 2026.
- How has Amphastar Pharmaceuticals's EBITDA margin changed year-over-year?
- Amphastar Pharmaceuticals's EBITDA margin decreased by 28.9% year-over-year, from 34% to 24.2%.
- What is the long-term trend for Amphastar Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's EBITDA margin has grown at a 24.1% compound annual growth rate (CAGR), from 9.3% to 27.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.